PPMD Expands Leadership with Appointment of Katherine Beaverson as CEO

Rare Daily Staff

Parent Project Muscular Dystrophy named Katherine Beaverson, who has held multiple patient advocacy positions at rare disease drug developers, as its CEO.

Pat Furlong, the founding president and CEO of PPMD, will continue in her role as president.

Furlong announced the appointment in a letter posted on the PPMD website.

“Katherine has spent her career forging partnerships and building bridges — skills that will help us accelerate progress, bring new therapies to families faster, and ensure that our network of care continues to grow stronger and more connected,” Furlong wrote.

Beaverson, who began her career as a genetic counselor, has more than 25 years of experience in patient advocacy, public affairs, project management, program development, and medical communications/education in pharmaceutical and academic clinical settings.

Since the start of 2024, she has served as vice president of global patient advocacy for Dyne Therapeutics. Previously, she spent more than 10 years as the executive director of global rare disease patient advocacy lead at Pfizer. She also held patient advocacy positions at Boehringer Ingelheim and Amicus.

Earlier in her career, Beaverson worked as a genetic counselor at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center.